- Home
- IOVA vs BHC Comparison
IOVA vs BHC Comparison
Compare IOVA & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- BHC
- Stock Information
- Founded
- IOVA 2007
- BHC N/A
- Country
- IOVA United States
- BHC Canada
- Employees
- IOVA N/A
- BHC N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- BHC Biotechnology: Pharmaceutical Preparations
- Sector
- IOVA Health Care
- BHC Health Care
- Exchange
- IOVA Nasdaq
- BHC Nasdaq
- Market Cap
- IOVA 2.6B
- BHC 3.0B
- IPO Year
- IOVA N/A
- BHC N/A
- Fundamental
- Price
- IOVA $5.91
- BHC $7.44
- Analyst Decision
- IOVA Strong Buy
- BHC Hold
- Analyst Count
- IOVA 9
- BHC 4
- Target Price
- IOVA $23.33
- BHC $7.25
- AVG Volume (30 Days)
- IOVA 9.1M
- BHC 1.5M
- Earning Date
- IOVA 02-26-2025
- BHC 02-20-2025
- Dividend Yield
- IOVA N/A
- BHC N/A
- EPS Growth
- IOVA N/A
- BHC N/A
- EPS
- IOVA N/A
- BHC N/A
- Revenue
- IOVA $90,858,000.00
- BHC $9,474,000,000.00
- Revenue This Year
- IOVA $13,758.71
- BHC $10.68
- Revenue Next Year
- IOVA $171.20
- BHC $3.66
- P/E Ratio
- IOVA N/A
- BHC N/A
- Revenue Growth
- IOVA 12751.20
- BHC 10.91
- 52 Week Low
- IOVA $5.62
- BHC $3.96
- 52 Week High
- IOVA $18.33
- BHC $11.46
- Technical
- Relative Strength Index (RSI)
- IOVA 28.87
- BHC 41.17
- Support Level
- IOVA $5.62
- BHC $7.30
- Resistance Level
- IOVA $6.44
- BHC $8.03
- Average True Range (ATR)
- IOVA 0.45
- BHC 0.27
- MACD
- IOVA -0.10
- BHC -0.01
- Stochastic Oscillator
- IOVA 11.46
- BHC 14.29
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.